摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[2-[[4-bromo-2-[[6-(3-bromopropoxy)-7-methoxyquinazolin-4-yl]amino]-5-fluorophenyl]methyl-methylamino]ethyl]-2-nitrobenzenesulfonamide | 890532-83-9

中文名称
——
中文别名
——
英文名称
N-[2-[[4-bromo-2-[[6-(3-bromopropoxy)-7-methoxyquinazolin-4-yl]amino]-5-fluorophenyl]methyl-methylamino]ethyl]-2-nitrobenzenesulfonamide
英文别名
——
N-[2-[[4-bromo-2-[[6-(3-bromopropoxy)-7-methoxyquinazolin-4-yl]amino]-5-fluorophenyl]methyl-methylamino]ethyl]-2-nitrobenzenesulfonamide化学式
CAS
890532-83-9
化学式
C28H29Br2FN6O6S
mdl
——
分子量
756.447
InChiKey
UFFPONJCAAGYDU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.6
  • 重原子数:
    44
  • 可旋转键数:
    14
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    160
  • 氢给体数:
    2
  • 氢受体数:
    12

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI
    申请人:Freyne Eddy Jean Edgard
    公开号:US20100152174A1
    公开(公告)日:2010-06-17
    The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z represents NH; Y represents —C 3-9 alkyl-, —C 1-5 alkyl-NR 13 —C 1-5 alkyl-, —C 1-5 alkyl-NR 14 —CO—C 1-5 alkyl-, —C 1-2 alkyl-NR 21 —H 2 —CO—NH—C 1-3 alkyl- or —C 1-2 alkyl-NR 23 —CO—CR 16 R 17 —NH—; X 1 represents O or —O—C 1-2 alkyl-; X 2 represents a direct bond, C 1-2 alkyl, —CO—C 1-2 alkyl or NR 12 —C 1-2 alkyl; R 1 represents hydrogen or halo; R 2 represents halo, acetylene or Het 1 ; R 3 represents hydrogen or cyano; R 4 represents Ar 4 —C 1-4 alkyloxy-, C 1-4 alkyloxy- or C 1-4 alkyloxy substituted with one or where possible two or more substituents selected from Het 2 , NR 7 R 8 , hydroxy and C 1-4 alkyloxy-C 1-4 alkyloxy-; R 7 represents hydrogen or C 1-4 alkyl; R 8 represents C 1-4 alkyl substituted with NR 25 R 26 or C 1-4 alkylsulfonyl; R 12 represents hydrogen or C 1-4 alkyl-; R 13 represents Ar 6 -sulfonyl or C 1-6 alkyloxycarbonyl optionally substituted with phenyl; R 16 and R 17 represents hydrogen, C 1-4 alkyl or R 16 and R 17 taken together with the carbon atom to which they are attached from a C 3-6 cycloalkyl; R 23 represents C 1-4 alkyl and R 23 represents hydrogen when R 16 and R 17 taken together with the carbon atom to which they are attached from a C 3-6 cycloalkyl; R 25 , R 26 , R 27 and R 28 each independently represent hydrogen or C 1-4 alkylcarbonyl; Het 1 represents 2 -bora- 1,3 -dioxolanyl; Het represents piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl or 1,1 -dioxothiomorpholinyl wherein said Het 2 is optionally substituted with C 1-4 alkyloxycarbonyl or NR 27 R 28 —C 1-4 alkyl; Ar 4 and Ar 5 represents phenyl; Ar 6 represents phenyl optionally substituted with nitro.
    本发明涉及式(I)化合物,其N-氧化物形式,药学上可接受的加成盐和立体化学异构体形式,其中Z代表NH; Y代表-C3-9烷基,-C1-5烷基-NR13-C1-5烷基,-C1-5烷基-NR14-CO-C1-5烷基,-C1-2烷基-NR21-H2-CO-NH-C1-3烷基或-C1-2烷基-NR23-CO-CR16R17-NH-; X1代表O或-O-C1-2烷基; X2代表直接键,C1-2烷基,-CO-C1-2烷基或NR12-C1-2烷基; R1代表氢或卤素; R2代表卤素,乙炔或Het1; R3代表氢或氰基; R4代表Ar4-C1-4烷氧基,C1-4烷氧基或C1-4烷氧基,其中可能有一或更多取代基选自Het2,NR7R8,羟基和C1-4烷氧基-C1-4烷氧基-; R7代表氢或C1-4烷基; R8代表C1-4烷基,取代为NR25R26或C1-4烷基磺酰基; R12代表氢或C1-4烷基-; R13代表Ar6-磺酰基或C1-6烷氧羰基,可选地取代苯基; R16和R17代表氢,C1-4烷基或R16和R17与它们连接的碳原子组成C3-6环烷基; R23代表C1-4烷基,当R16和R17与它们连接的碳原子组成C3-6环烷基时,R23代表氢; R25,R26,R27和R28分别独立地代表氢或C1-4烷基羰基; Het1代表2-硼-1,3-二氧杂环丙基; Het代表哌啶基,哌嗪基,吗啉基,硫代吗啉基或1,1-二氧硫代吗啉基,其中所述的Het2可选地取代为C1-4烷氧羰基或NR27R28-C1-4烷基; Ar4和Ar5代表苯基; Ar6代表可选地取代为硝基的苯基。
  • US20140256714A1
    申请人:——
    公开号:US20140256714A1
    公开(公告)日:2014-09-11
  • US9688691B2
    申请人:——
    公开号:US9688691B2
    公开(公告)日:2017-06-27
  • WO2006/61417
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多